ProShare Advisors
PLRX icon

ProShare Advisors’s Pliant Therapeutics PLRX Stock Holding History

ProShare Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,080
Closed -$20.4K – 2159
2025
Q1 		$20.4K Sell
15,080
-3,851
-20% -$23.4K ﹤0.01% 2037
2024
Q4 		$249K Buy
18,931
+4,570
+32% +$62.4K ﹤0.01% 1765
2024
Q3 		$161K Buy
14,361
+2,982
+26% +$37.3K ﹤0.01% 1786
2024
Q2 		$122K Sell
11,379
-3,110
-21% -$40.1K ﹤0.01% 1631
2024
Q1 		$216K Buy
14,489
+1,203
+9% +$19.8K ﹤0.01% 1631
2023
Q4 		$241K Buy
13,286
+2,033
+18% +$30.9K ﹤0.01% 1536
2023
Q3 		$195K Buy
11,253
+76
+0.7% +$1.32K ﹤0.01% 1477
2023
Q2 		$203K Buy
+11,177
New +$265K ﹤0.01% 1536
2022
Q1 		– Sell
-10,335
Closed -$139K – 2280
2021
Q4 		$139K Sell
10,335
-424
-4% -$6.74K ﹤0.01% 2145
2021
Q3 		$182K Sell
10,759
-1,933
-15% -$41K ﹤0.01% 1812
2021
Q2 		$370K Buy
12,692
+1,364
+12% +$42.5K ﹤0.01% 1748
2021
Q1 		$446K Buy
+11,328
New +$368K ﹤0.01% 1522

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

ProShare Advisors's PLRX Position: Q2 2025 in Review

ProShare Advisors sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 15,080 shares — an estimated $20.4K sold.

ProShare Advisors first reported a position in PLRX in Q1 2021 and held it in 12 quarters. The position peaked at $446K in Q1 2021. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

  • ProShare Advisors reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 15,080 Pliant Therapeutics shares in Q2 2025, an estimated $20.4K.
  • ProShare Advisors first reported a position in Pliant Therapeutics in Q1 2021 and held it in 12 quarters.
  • ProShare Advisors's Pliant Therapeutics position peaked at $446K in Q1 2021.
  • 114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.